CVRx (CVRX) Cash from Investing Activities (2020 - 2026)
CVRx's (CVRX) quarterly Cash from Investing Activities came in at -$122000.0 in Q1 2026, down 7.02% year-on-year from -$131207.5 in Q1 2025, and down 79.41% quarter-over-quarter from -$68000.0 in Q4 2025.
CVRx (CVRX) Cash from Investing Activities (2020 - 2026) Analysis & Trends
CVRx's Cash from Investing Activities history runs 7 years deep, the most recent figure standing at -$122000.0 for Q1 2026.
- On a quarterly basis, Cash from Investing Activities fell 7.02% year-over-year to -$122000.0 in Q1 2026; TTM through Mar 2026 was -$588000.0, a 5.38% decrease from a year earlier, with the FY2025 full-year figure at -$580000.0, up 57.38% from the prior year.
- Cash from Investing Activities eased to -$122000.0 in Q1 2026 per CVRX's latest filing, from -$68000.0 in the prior quarter.
- Across five years, Cash from Investing Activities topped out at -$37000.0 in Q3 2024 and bottomed at -$917000.0 in Q1 2024.
- The 5-year median for Cash from Investing Activities is -$122000.0 (2026), against an average of -$196411.8.
- Biggest YoY gain for Cash from Investing Activities was 87.57% in 2025; the steepest drop was 697.3% in 2025.
- Year by year, Cash from Investing Activities stood at -$79000.0 in 2022, then tumbled by 113.92% to -$169000.0 in 2023, then surged by 69.23% to -$52000.0 in 2024, then slumped by 30.77% to -$68000.0 in 2025, then slumped by 79.41% to -$122000.0 in 2026.
- Per Business Quant, the three latest CVRX Cash from Investing Activities figures stand at -$122000.0 (Q1 2026), -$68000.0 (Q4 2025), and -$295000.0 (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 182.32 Bn | 175.02 Bn | 6.27 Bn | -20.32 Bn |
| 2 | Stryker | 128.75 Bn | 125.88 Bn | 3.81 Bn | -185.00 Mn |
| 3 | Medtronic | 107.83 Bn | 98.61 Bn | 6.41 Bn | -917.00 Mn |
| 4 | Boston Scientific | 67.61 Bn | 66.15 Bn | 3.61 Bn | -591.00 Mn |
| 5 | Edwards Lifesciences | 48.13 Bn | 44.45 Bn | 1.29 Bn | -92.80 Mn |
| 6 | Dexcom | 28.26 Bn | 27.14 Bn | 750.30 Mn | -298.50 Mn |
| 7 | GE HealthCare Technologies | 27.78 Bn | 25.50 Bn | 1.98 Bn | -2.50 Bn |
| 8 | Smith & Nephew | 26.99 Bn | 26.41 Bn | - | - |
| 9 | Koninklijke Philips | 23.92 Bn | 20.80 Bn | 2.07 Bn | -475.32 Mn |
| 10 | CVRx | 128.88 Mn | 56.58 Mn | 12.88 Mn | -122,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -122,000.00 |
| Mar 31, 2026 | -122,000.00 |
| Dec 31, 2025 | -68,000.00 |
| Dec 31, 2025 | -68,000.00 |
| Sep 30, 2025 | -295,000.00 |
| Sep 30, 2025 | -295,000.00 |
| Jun 30, 2025 | -103,000.00 |
| Jun 30, 2025 | -103,000.00 |
| Mar 31, 2025 | -114,000.00 |
| Mar 31, 2025 | -114,000.00 |
| Dec 31, 2024 | -52,000.00 |
| Dec 31, 2024 | -52,000.00 |
| Sep 30, 2024 | -37,000.00 |
| Sep 30, 2024 | -37,000.00 |
| Jun 30, 2024 | -355,000.00 |
| Jun 30, 2024 | -355,000.00 |
| Mar 31, 2024 | -917,000.00 |
| Mar 31, 2024 | -917,000.00 |
| Dec 31, 2023 | -169,000.00 |
| Dec 31, 2023 | -169,000.00 |